Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry

Zhili Zheng1, Nachimuthu Chinnasamy, Richard A Morgan

  • 1Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Abstract

Insights

Protein L offers a universal flow cytometry method for detecting chimeric antigen receptors (CARs) on engineered lymphocytes. This approach provides consistent and reliable detection of CAR expression, advancing adoptive immunotherapy research.

Area of Science:

  • Immunology
  • Molecular Biology
  • Biotechnology

Background:

  • Chimeric antigen receptors (CARs) are crucial in adoptive immunotherapy for targeting tumor antigens.
  • Current methods for detecting CAR expression on lymphocytes have limitations, including reagent availability and consistency issues.
  • A universal flow cytometry method for CAR detection is needed to support ongoing clinical trials.

Purpose of the Study:

  • To develop a simple and universal flow cytometry method for detecting CAR expression on transduced lymphocytes.
  • To evaluate the efficacy of Protein L as a reagent for CAR detection.

Main Methods:

  • Utilized Protein L, an immunoglobulin-binding protein, to detect CARs on gene-modified lymphocytes.
  • Protein L binds to the variable light chains of immunoglobulin without affecting the antigen-binding site.
  • Validated the method using CARs derived from human, murine, and humanized mouse antibodies.

Main Results:

  • Protein L-based flow cytometry successfully detected CAR expression on transduced lymphocytes, with specific staining patterns observed.
  • Results correlated well with established methods, including anti-Fab antibodies and CAR-specific fusion proteins.
  • Detected CAR expression on 40-80% of transduced lymphocytes, demonstrating broad applicability across different CAR types.

Conclusions:

  • Protein L is a feasible and effective general reagent for detecting CAR expression on transduced lymphocytes.
  • This method offers a standardized approach for monitoring CAR-modified cells in adoptive immunotherapy.

Related Concept Videos